Diligence memo · auto-generated · as of July 2, 2026
Antigenics LLC/DE
Antigenics LLC/DE looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Antigenics LLC/DE operates in Biotechnology, based in LEXINGTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Antigenics LLC/DE has raised $100M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $100M on 2015-09-08.
Most recent recorded round closed around 2015-09-08.
Valuation (modeled)modeled
Provath models Antigenics LLC/DE at approximately $4.1B (range $309M–$10.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.81× the median modeled value of Series C Biotechnology companies in 2013–2015 (41 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 10.8 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 90% of Biotechnology peers (4293 compared).
Modeled value ranks above 98% of those peers.
Closest niche peers: Naurex Inc., Fluidigm Corp, Tengion Inc, Spark Therapeutics, Inc., X-Co Holdings, LP.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.